In 106 people aged 10 or older with advanced Duchenne muscular dystrophy, intravenous deramiocel every 3 months improved upper-limb function (PUL2.0) at 12 months versus placebo by 4·55% (95% CI 0·47–8·63; p=0·029), with similar safety.
RCTn = 106
McDonald et al. Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial